Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: An early report

Gut

Volumn 47, Issue 5, 2000, Pages 694-697

  Zylberberg, H ^a   Pialoux, G ^c   Brechot, C ^a   Pol, S ^a   Benhamou, Y ^b   Lagneaux, J L ^a   Landau, A ^c   Chaix, M L ^a   Fontaine, H ^a   Bochet, M ^b   Poynard, T ^b   Katlama, C ^b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c Service des Vaccinations   (France)

Author keywords

Antiretroviral therapy; Hepatitis C virus; Human immunodeficiency virus; Ribavirin; Stavudine; Zidovudine

Indexed keywords

ALPHA INTERFERON; ANTIRETROVIRUS AGENT; INDINAVIR; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RIBAVIRIN; RITONAVIR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; ANEMIA; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HEMOGLOBIN DETERMINATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; MIXED INFECTION; PRIORITY JOURNAL; TREATMENT OUTCOME; VIREMIA; VIRUS LOAD;

ADULT; ANEMIA; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; MALE; POLYMERASE CHAIN REACTION; RECURRENCE; RETROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0033756205     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.47.5.694     Document Type: Article

References (13)

1. Reciprocal interactions between human immunodeficiency virus and hepatitis C virus infections
2. Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users
3. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C
4. Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C
5. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
6. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
7. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
8. Ribavirin antagonizes the effect of azidothymidine on HIV replication
9. Ribavirin antagonizes inhibitory effects of pyrimidine 2'3'-dideoxynucleosides but enhances inhibitory effects of purine 2',3'-dideoxynucleosides on replication of human immunodeficiency virus in vitro
10. Effects of drugs on 2',3'-didehydrothymidine phosphorylation in vitro
11. Comparison of ribavirin and placebo in CDC group III human immunodeficiency virus infection
12. A multicenter clinical trial of oral ribavirin in HIV-infected people with lymphadenopathy: Virologic observations
13. A randomized trial of ribavirin and interferon-α vs. interferon-α alone in patients with chronic hepatitis C who were non-responders to a previous treatment